Quantcast

Latest Applied genetics Stories

2011-04-13 00:00:27

Overcoming the gene silencing barrier opens doors for gene therapy. Lincoln, NE (PRWEB) April 12, 2011 NTC today announced the award of a Small Business Innovation Research (SBIR) Phase II grant award from the National Institute of General Medical Sciences. The award represents a continuation of a Phase I study, which initially demonstrated the feasibility of overcoming transgene silencing, previously, a major barrier to successful gene therapy. In addition to anti-silencing elements, the...

2011-04-12 18:20:00

FAIRFIELD, Ohio, April 12, 2011 /PRNewswire/ -- "Hello Truth" has meaning for Robert McClendon, DDC's (DNA Diagnostics Center) first Innocence Network exoneree who was freed through forensic DNA testing in 2008. Even more so after the April 10, 2011, DDC Forensics unveiling of DDC's newly named DNA analyzer, "Hello Truth," in honor of McClendon and his poem by the same name. Just prior to the surprise unveiling, McClendon recounted his first-person story to the many guests attending...

2011-03-24 05:00:00

FAIRFIELD, Ohio, March 24, 2011 /PRNewswire/ -- DDC (DNA Diagnostics Center), the largest provider of private paternity and other DNA testing in the U.S. and worldwide, announced today that genetics and molecular biology expert Dr. Richard Chmelo has joined the DDC team to spearhead the Company's expanded research and development efforts for the creation of groundbreaking new DNA tests. In addition, DDC has acquired new SNP (single nucleotide polymorphism) DNA testing instrumentation,...

2011-03-16 17:30:00

FORT LEE, N.J., March 16, 2011 /PRNewswire/ -- Neurologix, Inc. (OTC Bulletin Board: NRGX), announced today that the results of the Company's Phase 2 clinical trial for its novel, investigational gene therapy NLX-P101 for the treatment of Parkinson's disease (PD) were published in an online-first edition of The Lancet Neurology. The randomized, double-blind, sham surgery-controlled trial of 45 subjects with advanced PD met its primary outcome measurement for efficacy and demonstrated that...

2011-02-28 22:07:33

A Wayne State University School of Medicine physician-researcher has developed a personalized therapy to treat a wide range of cancers. The treatment is based on a naturally occurring human enzyme that has been genetically modified to fool cancer cells into killing themselves. The unique concept, patented by Wayne State University, was successfully demonstrated on melanoma cells that are resistant to routine treatments such as chemotherapy or radiotherapy. Melanoma is a perfect model for...

987cf216b55d6d58f0243ddd3fc2d1861
2011-02-15 13:30:00

Identigene announced on Tuesday that its DNA Paternity Test Kit is now available in New York pharmacies. Identigene first started selling its paternity test kit in major pharmacy chains three years ago.  The kit has been available in 49 states for over two years and is in over 16,000 stores. New York requires a physician or attorney's authorization for a paternity test and requires that the sample collection process be witnessed.  This policy has required people to perform...

2011-02-08 14:06:00

AMSTERDAM, February 8, 2011 /PRNewswire-FirstCall/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced today that it will release its financial results for the year ended December 31, 2010 on Wednesday, February 16, 2011 at 07:00 AM Central European Time (CET). To discuss these results, AMT's management will conduct a conference call at 3:30 PM CET, which will also be webcast. To participate in the conference call, please call...

2011-02-07 18:21:16

Defects in the genome are the cause of many diseases. Gene therapy "“ direct replacement of mutant genes by intact DNA copies "“ offers a means of correcting such defects. Now a research team based at the Medical Center of the University of Munich, and led by Privatdozent Dr. Carsten Rudolph, has taken a new approach that avoids DNA delivery. The team shows for the first time that chemical modification of mRNAs (the metabolically active molecules derived from genomic DNA that...

2011-01-10 07:00:00

CARLSBAD, Calif., Jan. 10, 2011 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced today that it will hold a conference call focused on Genzyme's recent regulatory discussions with the FDA about the mipomersen NDA filing. Genzyme plans to communicate at its JP Morgan presentation Tuesday that: It had a productive meeting with the FDA. Based on FDA feedback, it believes the mipomersen package for HoFH is sufficient for filing. Due to the size of the severe HeFH...

2011-01-10 00:00:00

AMSTERDAM, January 10, 2011 /PRNewswire-FirstCall/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in human gene therapy, announced today that it has entered into an agreement with Institut Pasteur, Paris, France, and a group of French research institutes (together the "Consortium") to support clinical development of a novel gene therapy to treat Sanfilippo B. This rare genetic disease affecting new-born children leads to progressive neuronal degeneration and death. There is...


Word of the Day
blee
  • Color; hue; complexion.
This word is Middle English in origin.
Related